Market Cap (In SEK)
44.82 Million
Revenue (In SEK)
50.48 Million
Net Income (In SEK)
-438 Thousand
Avg. Volume
84.13 Thousand
- Currency
- SEK
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.756-2.25
- PE
- -2.47
- EPS
- -0.26
- Beta Value
- 0.36
- ISIN
- SE0006343745
- CUSIP
- -
- CIK
- -
- Shares
- 69820100.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Johan Emilsson
- Employee Count
- -
- Website
- https://www.sprintbioscience.com
- Ipo Date
- 2014-11-07
- Details
- Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.
More Stocks
-
UGPA3
-
BLLB
-
DNET
-
DWAHF
-
2643
-
ALLAilleron S.A.
ALL
-
DLICY
-
300463Maccura Biotechnology Co.Ltd
300463